ArticleLancet (London, England)2016
Targeting tau protein in Alzheimer's disease.
Article in Lancet (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Mitochondrial DNA homeostasis: A novel therapeutic target for neurodegenerative diseases.Neural regeneration research · 2026Article
- Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease.Nutrients · 2025Review
- Novel Emerging Targets Identification in Reducing Risk of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Review
- Bioactive components and clinical potential ofFrontiers in pharmacology · 2025Review
- Amyloidogenesis: What Do We Know So Far?International journal of molecular sciences · 2022Review
- Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches.Biomolecules · 2022Article
- Differential expression of plasma exosomal microRNA in severe acute pancreatitis.Frontiers in pharmacology · 2022Article
- The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer’s Disease-Induced Cognitive DysfunctionIranian biomedical journal · 2020Review
- Neurogranin: A Potential Biomarker of Neurological and Mental Diseases.Frontiers in aging neuroscience · 2020Review
- A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.Scientific reports · 2019Article
- Tumor necrosis factor α Inhibition for Alzheimer's Disease.Journal of central nervous system disease · 2017Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27863808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.